Veteran biotech finance executive joins Cue to support the Company's next phase of clinical and corporate growth as the company advances regulatory filing for food allergy (GlobeNewswire) - Aug 3, 2026 - "Mr. Ahlers joins Cue at a pivotal point in the Company's evolution with a recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy and anticipated Phase 2 CSU data readout for the program by the end of the quarter."
IND • P2 data • Chronic Spontaneous Urticaria • Food Hypersensitivity
|